Alpha Cognition, Inc. is a clinical stage biopharmaceutical company that develops treatments for underserved neurodegenerative diseases such as Alzheimer's Dementia and Amyotrophic Lateral Sclerosis.

The sizeable new round follows the announcement of phase 1 data for its lead asset MET-097i in September, and according to ...